Real-world effectiveness and safety of direct-acting antivirals in hepatitis C virus patients with mental disorders

Table 3 Treatment characteristics in chronic hepatitis C patients with (group A) and without (group B) psychiatric disorders, %, n

Parameter	All patients (n = 14272)	Group A (n = 942)	Group B (n = 13330)	P value
History of antiviral treatment
Treatment-naïve	78.7 (11238)	80.6 (760)	78.6 (10478)	0.132 (χ2 = 2.2)
Nonresponder to IFN-based regimens	19.6 (2791)	16.7 (157)	19.8 (2634)	0.02 (χ2 = 5.3)
Nonresponder to IFN-free regimens	1.7 (247)	2.7 (25)	1.6 (222)	0.02 (χ2 = 5.1)
Current treatment regimen
Pangenotypic regimens	35.2 (5028)	43.0 (405)	34.7 (4619)	< 0.0001 (χ2 = 26.0)
Genotype-specific regimens	64.8 (9248)	57.0 (537)	65.3 (8711)
Current-RBV-containing regimens	16.2 (2308)	16.5 (155)	16.1 (2153)	0.807 (χ2 = 0.05)
Genotype-specific treatment regimens
ASV + DCV	0.8 (118)	1.3 (12)	0.8 (106)	0.117 (χ2 = 2.5)
SOF/LDV ± RBV	19.6 (2795)	21.8 (205)	19.4 (2590)	0.081 (χ2 = 3.1)
OBV/PTV/r ± DSV ± RBV	25.4 (3626)	14.1 (133)	26.2 (3493)	< 0.0001 (χ2 = 67.8)
GZR/EBR ± RBV	16.8 (2400)	16.3 (154)	16.8 (2246)	0.691 (χ2 = 0.1)
Other SOF ± SMV ± DCV ± RBV, SMV ± DCV ± RBV	2.2 (305)	3.2 (33)	2.1 (272)	0.02 (χ2 = 5.7)
Pangenotypic regimens
GLE/PIB	20.6 (2940)	20.6 (194)	20.6 (2746)	0.997 (χ2 = 0.0)
GLE/PIB + SOF + RBV	0.05 (6)	0.0 (0)	0.05 (6)	1.0
SOF/VEL ± RBV	14.4 (2058)	22.2 (209)	13.9 (1849)	< 0.0001 (χ2 = 49.3)
SOF/VEL/VOX	0.2 (24)	0.2 (2)	0.2 (22)	0.670

The reported P value relates to Pearson’s chi-square test or Fisher’s exact test if the number of observations in the category was less than 10. CHC: Chronic hepatitis C; IFN: Interferon; RBV: Ribavirin; ASV: Asunaprevir; DCV: Daclatasvir; LDV: Ledipasvir; SOF: Sofosbuvir; OBV: Ombitasvir; PTV: Paritaprevir; r: Ritonavir; DSV: Dasabuvir; GZR: Grazoprevir; EB: Elbasvir; SMV: Simeprevir; GLE: Glecaprevir; PIB: Pibrentasvir; VEL: Velpatasvir; VOX: Voxilaprevir.